Literature DB >> 1432029

The 56 kd platelet-derived growth factor (PDGF)-related protein is phosphorylated and the most stable form in human glioma cells.

T Nakamura1, I Takeshita, T Inamura, M Fukui.   

Abstract

We report herein the presence of a 56 kd platelet derived growth factor (PDGF)-related protein as a phosphorylated form in human glioma cells. The phosphorylation of the 56 kd form was found to be the longest of all PDGF-related proteins. By Western blotting using a monoclonal anti-PDGF B-chain, the 80 kd, 56 kd, 40 kd, 28 kd and 17 kd PDGF-related proteins were detected, while after treatment among the nitrocellulose membrane transblotted cell extracts with alkaline phosphatase, 40 kd was the most densely observed while the 56 kd and 80 kd PDGF-related proteins were also detected. In a 32P flush labeling study, it was revealed that PDGF-related proteins incorporated with 32P were detected at 28, 32, 35, 40, 56 and 80 kd but the 17 kd monomer was not labeled. Among the labeled PDGF-related proteins, the 56 kd PDGF-related protein alone remained intracellularly for at least 16 hours. These results indicated that the PDGF-related proteins in human glioma cells are synthesized in a phosphorylated form and partly remain in a 56 kd phosphorylated form intracellularly. The 56 kd form may thus be the most stable form and likely has a substantial biological effect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1432029     DOI: 10.1007/bf00172759

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

1.  Glioma-derived PDGF-related protein presents as 17 kd intracellularly and assembled form induces actin reorganization.

Authors:  T Nakamura; I Takeshita; M Fukui
Journal:  J Neurooncol       Date:  1991-12       Impact factor: 4.130

2.  Detection of high molecular weight forms of platelet-derived growth factor by sequence-specific antisera.

Authors:  H L Niman; R A Houghten; D F Bowen-Pope
Journal:  Science       Date:  1984-11-09       Impact factor: 47.728

3.  Platelet-derived growth factor. I. High yield purification and evidence for multiple forms.

Authors:  E W Raines; R Ross
Journal:  J Biol Chem       Date:  1982-05-10       Impact factor: 5.157

4.  Platelet-derived growth factor: identification of constituent polypeptide chains.

Authors:  A Johnsson; C H Heldin; B Westermark; A Wasteson
Journal:  Biochem Biophys Res Commun       Date:  1982-01-15       Impact factor: 3.575

5.  Purification of human platelet-derived growth factor.

Authors:  H N Antoniades; C D Scher; C D Stiles
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

6.  Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation.

Authors:  M Hermansson; M Nistér; C Betsholtz; C H Heldin; B Westermark; K Funa
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

7.  Radioimmunoassay of human platelet-derived growth factor using monoclonal antibody toward a synthetic 73-97 fragment of its B-chain.

Authors:  T Shiraishi; S Morimoto; K Itoh; H Sato; K Sugihara; T Onishi; T Ogihara
Journal:  Clin Chim Acta       Date:  1989-09-15       Impact factor: 3.786

Review 8.  Properties of human malignant glioma cells in vitro.

Authors:  J Pontén; B Westermark
Journal:  Med Biol       Date:  1978-08

9.  Structural and immunological similarities between simian sarcoma virus gene product(s) and human platelet-derived growth factor.

Authors:  K C Robbins; H N Antoniades; S G Devare; M W Hunkapiller; S A Aaronson
Journal:  Nature       Date:  1983 Oct 13-19       Impact factor: 49.962

10.  Isoform-specific induction of actin reorganization by platelet-derived growth factor suggests that the functionally active receptor is a dimer.

Authors:  A Hammacher; K Mellström; C H Heldin; B Westermark
Journal:  EMBO J       Date:  1989-09       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.